Famitinib
Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers. In China, in May 2025 famitinib was conditionally approved for use in combination with camrelizumab for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.